-
A drug which has been used for decades to treat high blood pressure may turn out to be a key treatment for multiple sclerosis, say British researchers.
-
Neutralizing antibody (NAbs) positivity does not reduce the efficacy of interferon beta-1b (IFNbeta-1b) treatment, according to results of a substudy analysis of patients with a first event suggestive of multiple sclerosis (MS) in a multicentre, randomize
-
In the past few years, it has been shown that many drugs are not equally effective for every patient, and this variability is due, at least in part, to genetic differences.
-
Momenta's second generic product candidate is M356, a technology-enabled generic version of Copaxone (glatiramer acetate), a complex drug consisting of a mixture of polypeptide chains. Copaxone is indicated for the reduction of the frequency of relapses
-
The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment.
-
England's public-health watchdog group has recommended that their drug Tysabri be used to treat a debilitating form of multiple sclerosis.
-
Biogen Idec Inc. (BIIB.O: Quote, Profile , Research) reported second-quarter earnings that topped expectations on Tuesday, helped by higher sales of its drugs for multiple sclerosis and cancer and a lower tax rate.
-
The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS.
-
Savitex, an oral spray developed by the drugs company GW Pharmaceuticals, is now unlikely to gain regulatory approval in this country until 2009 despite recently winning full regulatory approval in Canada
-
TRIMESTA (oral estriol), its proprietary therapy for multiple sclerosis (MS), in a multi-center Phase II/III clinical trial for the treatment of women with relapsing-remitting MS.
-
How long do I have to stop injecting Avonex before getting pregnant?
-
A lack of funding has forced a Cardiff-based MS service to start a waiting list for patients who could benefit from beta interferon and copaxone.
-
Because many programs use one's qualification for SSDI or SSI as the criteria for their help, I fall through the cracks repeatedly.
-
"I have had MS for 25 years and although I have remained fairly stable I find that I am prone to periods of depression."
-
The MS-F204 study, which is conducted under a Special Protocol Assessment (SPA) issued by the Food and Drug Administration (FDA), will evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with MS.
